MX359398B - Compuestos para transduccion viral mejorada. - Google Patents

Compuestos para transduccion viral mejorada.

Info

Publication number
MX359398B
MX359398B MX2014003923A MX2014003923A MX359398B MX 359398 B MX359398 B MX 359398B MX 2014003923 A MX2014003923 A MX 2014003923A MX 2014003923 A MX2014003923 A MX 2014003923A MX 359398 B MX359398 B MX 359398B
Authority
MX
Mexico
Prior art keywords
viral transduction
methods
compounds
cells
compositions
Prior art date
Application number
MX2014003923A
Other languages
English (en)
Other versions
MX2014003923A (es
Inventor
Collins Heffner Garrett
Isaac Bassan Abraham
Original Assignee
Bluebird Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47996444&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX359398(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bluebird Bio Inc filed Critical Bluebird Bio Inc
Publication of MX2014003923A publication Critical patent/MX2014003923A/es
Publication of MX359398B publication Critical patent/MX359398B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/867—Retroviral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/02—Compounds of the arachidonic acid pathway, e.g. prostaglandins, leukotrienes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
    • C12N2810/6072—Vectors comprising as targeting moiety peptide derived from defined protein from viruses negative strand RNA viruses
    • C12N2810/6081—Vectors comprising as targeting moiety peptide derived from defined protein from viruses negative strand RNA viruses rhabdoviridae, e.g. VSV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a métodos y composiciones para mejorar la eficacia de transducción viral de células. Más particularmente, la presente invención proporciona métodos y materiales útiles para mejorar de manera segura y confiable la eficiencia de métodos para transducir células, tales como células madre hematopoyéticos (HSC) humanos, con virus y/o vectores virales. Las composiciones y métodos son útiles para indicaciones terapéuticas susceptibles de tratamiento con genoterapias de células madre hematopoyéticos.
MX2014003923A 2011-09-30 2012-09-28 Compuestos para transduccion viral mejorada. MX359398B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161541736P 2011-09-30 2011-09-30
PCT/US2012/057987 WO2013049615A1 (en) 2011-09-30 2012-09-28 Compounds for improved viral transduction

Publications (2)

Publication Number Publication Date
MX2014003923A MX2014003923A (es) 2014-05-07
MX359398B true MX359398B (es) 2018-09-27

Family

ID=47996444

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2014003923A MX359398B (es) 2011-09-30 2012-09-28 Compuestos para transduccion viral mejorada.
MX2018011791A MX2018011791A (es) 2011-09-30 2014-03-31 Compuestos para transduccion viral mejorada.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2018011791A MX2018011791A (es) 2011-09-30 2014-03-31 Compuestos para transduccion viral mejorada.

Country Status (19)

Country Link
US (5) US9988644B2 (es)
EP (4) EP2760994B2 (es)
JP (2) JP6285863B2 (es)
KR (1) KR102011532B1 (es)
CN (2) CN108220246B (es)
AU (1) AU2012315699B2 (es)
BR (1) BR112014007782B1 (es)
CA (1) CA2850484C (es)
CY (1) CY1122654T1 (es)
DK (2) DK3269802T3 (es)
EA (1) EA032699B1 (es)
ES (3) ES2632444T5 (es)
IL (2) IL231812B (es)
IN (1) IN2014CN02518A (es)
MX (2) MX359398B (es)
PT (2) PT2760994T (es)
SG (2) SG11201401077PA (es)
UA (1) UA114796C2 (es)
WO (1) WO2013049615A1 (es)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3824884A1 (en) 2008-11-06 2021-05-26 Indiana University Research and Technology Corporation Materials and methods to enhance hematopoietic stem cells engraftment procedures
KR102011532B1 (ko) 2011-09-30 2019-08-16 블루버드 바이오, 인코포레이티드. 개선된 바이러스 형질도입을 위한 화합물
CA2880811C (en) 2012-08-01 2021-12-07 United Therapeutics Corporation Treatment of pulmonary arterial hypertension with prostacyclin-treated endothelial progenitor cells
WO2014022373A1 (en) * 2012-08-01 2014-02-06 United Therapeutics Corporation Treatment of pulmonary arterial hypertension with mesenchymal stem cells
US20150216903A1 (en) * 2012-08-10 2015-08-06 Bluebird Bio, Inc. Compounds for improved viral transduction
DK2925864T3 (en) 2012-11-27 2019-02-11 Childrens Medical Ct Corp DIRECTIONAL TARGETING OF DISTANT BCL11A CONTROLS FOR FETAL HEMOGLOBIN REINUCTION
EP3878452B1 (en) 2013-01-09 2023-09-20 United Therapeutics Corporation Treatment of vasculopathy with prostacyclin and mesenchymal stem cells
EP3613859A1 (en) * 2013-10-24 2020-02-26 Ospedale San Raffaele S.r.l. Method
CN106455542A (zh) * 2014-03-26 2017-02-22 布里格姆及妇女医院股份有限公司 用于人造血干/祖细胞的离体扩增的组合物和方法
CA2946309C (en) 2014-04-25 2021-11-09 Michael MILSOM Synthetic bcl11a micrornas for treating hemoglobinopathies
WO2016182917A1 (en) 2015-05-08 2016-11-17 Children's Medical Center Corporation Targeting bcl11a enhancer functional regions for fetal hemoglobin reinduction
RU2630654C2 (ru) * 2015-07-29 2017-09-11 Федеральное государственное автономное образовательное учреждение высшего профессионального образования "Балтийский Федеральный Университет имени Иммануила Канта" (БФУ им. И. Канта) Способ хемогенетической регистрации и коррекции нейрогенеза на основе генетических конструкций для трансфекции астроцитов и нейронов
CN105062979A (zh) * 2015-08-21 2015-11-18 昆明理工大学 一种培养戊型肝炎病毒的方法
EP3414321B8 (en) * 2016-02-12 2023-05-03 bluebird bio, Inc. Vcn enhancer compositions and methods of using the same
CN108883136A (zh) * 2016-02-12 2018-11-23 蓝鸟生物公司 Vcn增强子组合物及其使用方法
JP2019510503A (ja) * 2016-04-07 2019-04-18 ブルーバード バイオ， インコーポレイテッド キメラ抗原受容体ｔ細胞組成物
EP3452170A4 (en) 2016-05-05 2020-04-01 Liquidia Technologies, Inc. DRY POWDER OF TREPROSTINIL FOR THE TREATMENT OF PULMONARY HYPERTENSION
ES2927406T3 (es) 2016-10-24 2022-11-04 United Therapeutics Corp Potenciación de las propiedades inmunomoduladoras de las MSC mediante treprostinil
AU2017368050A1 (en) 2016-11-29 2019-06-20 Puretech Lyt, Inc. Exosomes for delivery of therapeutic agents
US11261441B2 (en) 2017-03-29 2022-03-01 Bluebird Bio, Inc. Vectors and compositions for treating hemoglobinopathies
WO2018183692A1 (en) * 2017-03-29 2018-10-04 Bluebird Bio, Inc. Vectors and compositions for treating hemoglobinopathies
US11788087B2 (en) 2017-05-25 2023-10-17 The Children's Medical Center Corporation BCL11A guide delivery
EP3681887B1 (en) * 2017-09-15 2024-09-04 The Medical College of Wisconsin, Inc. Kidney-targeted epoxyeicosatrienoic acid (eet) analogs
FR3074189A1 (fr) * 2017-11-30 2019-05-31 Assistance Publique - Hopitaux De Paris Methode de generation de greffons de cellules souches hematopoietiques
WO2019196816A1 (zh) * 2018-04-13 2019-10-17 诺未科技（北京）有限公司 丁酸钠的用途及含有丁酸钠的培养体系
CN109207427B (zh) * 2018-09-17 2020-12-08 诺未科技（银川）有限公司 一种将人造血祖细胞转变为造血干细胞的方法
JP2021522278A (ja) * 2018-04-27 2021-08-30 ザ メディカル カレッジ オブ ウィスコンシン インクＴｈｅ Ｍｅｄｉｃａｌ Ｃｏｌｌｅｇｅ Ｏｆ Ｗｉｓｃｏｎｓｉｎ， Ｉｎｃ． ライソゾーム病を改善するための、レンチウイルスベクターが形質導入されたｔ−ｒａｐａ細胞の使用
US20220389448A1 (en) * 2019-06-28 2022-12-08 The Children's Hospital Of Philadelphia Compositions and methods for treating anemia
CA3157966A1 (en) * 2019-10-16 2021-04-22 Orchard Therapeutics (Europe) Limited Compositions and methods for modifying eukaryotic cells
BR112022024625A2 (pt) * 2020-06-02 2023-02-23 Catalent Pharma Solutions Llc Construtos de ácido nucleico para a fabricação de proteína
CN113106098B (zh) * 2021-04-21 2022-04-01 贵州医科大学 一种在红系细胞中特异表达人β珠蛋白的重组序列及其应用
AU2021202658A1 (en) 2021-04-28 2022-11-17 Fondazione Telethon Gene therapy
CN113336833A (zh) * 2021-06-04 2021-09-03 广州伯尼兹生物科技有限公司 一种高效分泌表达猪流行性腹泻病毒s1蛋白的生产方法
WO2023133595A2 (en) 2022-01-10 2023-07-13 Sana Biotechnology, Inc. Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
GB202206346D0 (en) 2022-04-29 2022-06-15 Ospedale San Raffaele Srl Gene therapy
WO2024033802A2 (en) 2022-08-11 2024-02-15 Fondazione Telethon Ets Gene therapy
WO2024079644A1 (en) 2022-10-11 2024-04-18 Fondazione Telethon Ets 3d cell culture methods
WO2024081820A1 (en) 2022-10-13 2024-04-18 Sana Biotechnology, Inc. Viral particles targeting hematopoietic stem cells
WO2024119157A1 (en) 2022-12-02 2024-06-06 Sana Biotechnology, Inc. Lipid particles with cofusogens and methods of producing and using the same

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US568159A (en) 1896-06-26 1896-09-22 Veneering-machine
FR901228A (fr) 1943-01-16 1945-07-20 Deutsche Edelstahlwerke Ag Système d'aimant à entrefer annulaire
US4873192A (en) 1987-02-17 1989-10-10 The United States Of America As Represented By The Department Of Health And Human Services Process for site specific mutagenesis without phenotypic selection
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5399493A (en) 1989-06-15 1995-03-21 The Regents Of The University Of Michigan Methods and compositions for the optimization of human hematopoietic progenitor cell cultures
US5725871A (en) 1989-08-18 1998-03-10 Danbiosyst Uk Limited Drug delivery compositions comprising lysophosphoglycerolipid
US5707644A (en) 1989-11-04 1998-01-13 Danbiosyst Uk Limited Small particle compositions for intranasal drug delivery
US5061620A (en) 1990-03-30 1991-10-29 Systemix, Inc. Human hematopoietic stem cell
US5466468A (en) 1990-04-03 1995-11-14 Ciba-Geigy Corporation Parenterally administrable liposome formulation comprising synthetic lipids
US5635387A (en) 1990-04-23 1997-06-03 Cellpro, Inc. Methods and device for culturing human hematopoietic cells and their precursors
US5399363A (en) 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
US5756353A (en) 1991-12-17 1998-05-26 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol-and liposome-based delivery
US5460964A (en) 1992-04-03 1995-10-24 Regents Of The University Of Minnesota Method for culturing hematopoietic cells
DE69312487T2 (de) 1992-05-18 1997-11-27 Minnesota Mining & Mfg Einrichtung zur transmucosalen wirkstoffabgabe
US5877288A (en) 1993-06-21 1999-03-02 The Uab Research Foundation Anti-sickling hemoglobin
US5543158A (en) 1993-07-23 1996-08-06 Massachusetts Institute Of Technology Biodegradable injectable nanoparticles
US5409813A (en) 1993-09-30 1995-04-25 Systemix, Inc. Method for mammalian cell separation from a mixture of cell populations
US5869039A (en) 1993-10-15 1999-02-09 Institut National De La Sante Et De La Recherche Medicale X-linked adrenoleukodystrophy gene and corresponding protein
WO1996009385A1 (en) 1994-09-19 1996-03-28 Massachusetts Institute Of Technology Anti-sickling beta-globin protein, compositions and methods for treating sickle cell disease
US5677136A (en) 1994-11-14 1997-10-14 Systemix, Inc. Methods of obtaining compositions enriched for hematopoietic stem cells, compositions derived therefrom and methods of use thereof
IE80468B1 (en) 1995-04-04 1998-07-29 Elan Corp Plc Controlled release biodegradable nanoparticles containing insulin
ATE325533T1 (de) 1995-09-29 2006-06-15 Univ Indiana Res & Tech Corp Verfahren zum verbesserten virusvermittelten dns- transfer unter verwendung von molekülen mit virus-und zellbindenden domänen
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
US6057117A (en) 1996-04-04 2000-05-02 Chiron Corporation Identification and use of selective inhibitors of glycogen synthase kinase 3
EP0915975A2 (en) 1996-07-03 1999-05-19 Chiron Corporation Methods for administration of recombinant gene delivery vehicles for treatment of hemophilia
US5994136A (en) 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
FR2777909B1 (fr) 1998-04-24 2002-08-02 Pasteur Institut Utilisation de sequences d'adn de structure triplex pour le tranfert de sequences de nucleotides dans des cellules, vecteurs recombinants contenant ces sequences triplex
AU6339399A (en) 1998-10-16 2000-05-08 Novartis Ag Promotion of self-renewal and improved gene transduction of hematopoietic stem cells by histone deacetylase inhibitors
WO2000038663A2 (en) 1998-12-24 2000-07-06 Alcon Laboratories, Inc. Ep4 receptor agonists for treatment of dry eye
US7015037B1 (en) 1999-08-05 2006-03-21 Regents Of The University Of Minnesota Multiponent adult stem cells and methods for isolation
EP1219600A4 (en) 1999-08-13 2004-11-03 Taisho Pharmaceutical Co Ltd PROSTAGLANDIN DERIVATIVES
AU784195B2 (en) 1999-11-12 2006-02-16 Baxter Biotech Technology S.A.R.L. Reduced side-effect hemoglobin compositions
KR100688308B1 (ko) 1999-12-17 2007-02-28 노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드 글리코겐 신타아제 키나제3의 피라진 기제 저해제
ATE327751T1 (de) 2000-01-31 2006-06-15 Pfizer Prod Inc Verwendung von aktivatoren des prostaglandinrezeptores 4 zur behandlung von akuter oder chronischer niereninsuffizienz
US20020013294A1 (en) 2000-03-31 2002-01-31 Delong Mitchell Anthony Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives
WO2008108741A1 (en) 2007-03-07 2008-09-12 S*Bio Pte Ltd Combination of benzimidazole anti-cancer agent and a second anti-cancer agent
CA2446110C (en) 2001-05-01 2013-06-25 National Research Council Of Canada A system for inducible expression in eukaryotic cells
EP1461087A1 (en) 2001-12-06 2004-09-29 Institut National De La Sante Et De La Recherche Medicale (Inserm) Use of cd34+ hematopoietic progenitor cells for the treatment of cns disorders
WO2003056019A1 (en) 2001-12-24 2003-07-10 Es Cell International Pte Ltd Method of transducing es cells
EP1471818A4 (en) 2002-02-04 2007-03-28 Millennium Pharm Inc METHOD AND COMPOSITIONS FOR TREATING HEMATOLOGICAL DISEASES USING 131, 148, 199, 12303, 13906, 15513, 17822, 302, 5677, 194, 14393, 28059, 7366, 12212, 1981, 261, 12416, 270, 1410, 137 , 1871, 13051, 1847, 1849, 15402, 340, 10217, 837, 1761, 8990 OR 13249 MOLECULES
BR0313743A (pt) 2002-08-23 2005-07-05 Chiron Corp Benzimidazol quinolinonas e usos destas
US7119200B2 (en) 2002-09-04 2006-10-10 Schering Corporation Pyrazolopyrimidines as cyclin dependent kinase inhibitors
ES2348868T3 (es) 2002-12-13 2010-12-16 Genetix Pharmaceuticals Inc. Vectores retrovirales terapeuticos para terapia genica.
AU2004227205B2 (en) 2003-04-08 2010-06-10 Yeda Research And Development Co. Ltd Stem cells having increased sensitivity to a chemoattractant and methods of generating and using same
DE602004030105D1 (de) * 2003-05-05 2010-12-30 Virxsys Corp Erhöhte transduktion mit abc-transportersubstratenhemmern
US6747037B1 (en) 2003-06-06 2004-06-08 Allergan, Inc. Piperidinyl prostaglandin E analogs
IL158868A0 (en) 2003-11-13 2004-05-12 Yeda Res & Dev Methods of generating and using stem cells enriched with immature primitive progenitor
WO2006001463A1 (ja) 2004-06-23 2006-01-05 Ono Pharmaceutical Co., Ltd. Ｓ１ｐ受容体結合能を有する化合物およびその用途
JP2008518013A (ja) 2004-10-26 2008-05-29 アラーガン、インコーポレイテッド プロスタグランジンｅｐ４アゴニストによる処置方法およびデリバリー方法
US20080021078A1 (en) 2006-07-18 2008-01-24 Horizon Therapeutics, Inc. Methods and medicaments for administration of ibuprofen
US20070087988A1 (en) 2005-09-30 2007-04-19 New York University Hematopoietic progenitor kinase 1 for modulation of an immune response
WO2007047372A2 (en) 2005-10-14 2007-04-26 The Board Of Trustees Of The University Of Illinois Pharmacological treatments for sleep disorders (apnoe) with prostanoid receptor antagonists
DE102005062741A1 (de) 2005-12-22 2007-06-28 Bayer Schering Pharma Ag Fluorene und Carbazole als Liganden des EP2 Rezeptors
RU2425876C2 (ru) 2006-03-24 2011-08-10 Чилдрен'З Медикал Сентер Корпорейшн Способ модулирования роста гематопоэтических стволовых клеток
CA2650507A1 (en) * 2006-04-27 2007-11-08 Universite De Montreal Assessment and reduction of risk of graft-versus-host disease
CA2655807A1 (en) 2006-06-22 2007-12-27 Yeda Research And Development Co. Ltd Catecholamine receptor modulation
US9402852B2 (en) 2006-10-20 2016-08-02 Children's Medical Center Corporation Method to enhance tissue regeneration
US9394520B2 (en) 2006-12-08 2016-07-19 University Of Rochester Expansion of hematopoietic stem cells
WO2008126932A2 (en) 2007-04-09 2008-10-23 Riken Epigenetical regulation of brain plasticity
EP3824884A1 (en) * 2008-11-06 2021-05-26 Indiana University Research and Technology Corporation Materials and methods to enhance hematopoietic stem cells engraftment procedures
US20120202288A1 (en) 2009-03-19 2012-08-09 Fate Therapeutics, Inc. Compositions comprising cyclic amp enhancers and/or ep ligands, and methods of preparing and using the same
EP3575394A1 (en) * 2009-11-15 2019-12-04 Indiana University Research&Technology Corporation Methods to enhance delivery and engraftment of stem cells including the identification of specific prostaglandin e2 receptors
KR102011532B1 (ko) 2011-09-30 2019-08-16 블루버드 바이오, 인코포레이티드. 개선된 바이러스 형질도입을 위한 화합물
WO2014015318A1 (en) * 2012-07-19 2014-01-23 Bluebird Bio, Inc. Soluble compounds for improved gene therapy methods
US20150216903A1 (en) * 2012-08-10 2015-08-06 Bluebird Bio, Inc. Compounds for improved viral transduction
US9943545B2 (en) * 2013-03-15 2018-04-17 Fate Therapeutics, Inc. Stem cell culture media and methods of enhancing cell survival
EP3613859A1 (en) * 2013-10-24 2020-02-26 Ospedale San Raffaele S.r.l. Method
CN103937743B (zh) * 2014-04-27 2017-12-01 浙江大学 一种利用三维诱导系统获得造血干细胞的方法
JP6980534B2 (ja) * 2015-06-25 2021-12-15 ザ チルドレンズ メディカル センター コーポレーション 造血幹細胞の増大、富化、および維持に関する方法および組成物
RU2018106515A (ru) * 2015-07-21 2019-08-21 Зе Чилдрен'С Медикал Сентер Корпорейшн Pd-l1-экспрессирующие гемопоэтические стволовые клетки и применения
CN108883136A (zh) * 2016-02-12 2018-11-23 蓝鸟生物公司 Vcn增强子组合物及其使用方法
EP3414321B8 (en) * 2016-02-12 2023-05-03 bluebird bio, Inc. Vcn enhancer compositions and methods of using the same
GB201706394D0 (en) * 2017-04-21 2017-06-07 Ospedale San Raffaele Srl Gene Therapy
FR3074189A1 (fr) * 2017-11-30 2019-05-31 Assistance Publique - Hopitaux De Paris Methode de generation de greffons de cellules souches hematopoietiques

Also Published As

Publication number Publication date
AU2012315699B2 (en) 2017-08-17
CY1122654T1 (el) 2021-03-12
EP3269802A1 (en) 2018-01-17
EP2760994A4 (en) 2015-03-11
IL281045A (en) 2021-04-29
EA032699B1 (ru) 2019-07-31
IL281045B (en) 2022-02-01
ES2632444T3 (es) 2017-09-13
MX2018011791A (es) 2021-12-08
CN103958667A (zh) 2014-07-30
EP2760994A1 (en) 2014-08-06
IL231812B (en) 2021-03-25
US20140234278A1 (en) 2014-08-21
JP2018099124A (ja) 2018-06-28
JP2014530012A (ja) 2014-11-17
AU2012315699A1 (en) 2014-05-22
EA201490627A1 (ru) 2014-11-28
SG11201401077PA (en) 2014-04-28
ES2769270T3 (es) 2020-06-25
CA2850484A1 (en) 2013-04-04
WO2013049615A1 (en) 2013-04-04
KR20140069315A (ko) 2014-06-09
KR102011532B1 (ko) 2019-08-16
EP2760994B8 (en) 2017-07-26
EP3656848A1 (en) 2020-05-27
PT2760994T (pt) 2017-08-24
US10501759B2 (en) 2019-12-10
US11834668B2 (en) 2023-12-05
US10907177B2 (en) 2021-02-02
UA114796C2 (uk) 2017-08-10
EP2760994B2 (en) 2021-09-15
CN108220246A (zh) 2018-06-29
BR112014007782B1 (pt) 2021-06-01
JP6745826B2 (ja) 2020-08-26
EP2760994B1 (en) 2017-05-31
US20200048657A1 (en) 2020-02-13
US9988644B2 (en) 2018-06-05
EP3656848B1 (en) 2022-03-16
IN2014CN02518A (es) 2015-07-31
ES2913633T3 (es) 2022-06-03
JP6285863B2 (ja) 2018-02-28
PT3269802T (pt) 2020-01-28
DK2760994T3 (en) 2017-08-07
US20240229070A1 (en) 2024-07-11
SG10201602423TA (en) 2016-05-30
BR112014007782A2 (pt) 2017-04-11
US20210171980A1 (en) 2021-06-10
US20180363004A1 (en) 2018-12-20
EP4095236A1 (en) 2022-11-30
MX2014003923A (es) 2014-05-07
IL231812A0 (en) 2014-05-28
CA2850484C (en) 2021-01-26
NZ623341A (en) 2016-04-29
EP3269802B1 (en) 2019-10-23
ES2632444T5 (es) 2022-03-02
DK2760994T4 (da) 2021-10-11
DK3269802T3 (da) 2020-02-03
CN108220246B (zh) 2022-07-12

Similar Documents

Publication Publication Date Title
MX2018011791A (es) Compuestos para transduccion viral mejorada.
WO2014026110A3 (en) Compounds for improved viral transduction
MX2013014544A (es) Vectorales de terapia genica para adrenoleucodistrofia y adrenomieloneuropatia.
MX2022003116A (es) Factor ix modificado, y composiciones, metodos y usos para la transferencia de genes a celulas, organos y tejidos.
EA201891192A1 (ru) Средства и способы лечения миопатий, связанных с титином, и других титинопатий
GB201020995D0 (en) Biological materials and uses thereof
MX356525B (es) Vectores de virus asociados con adeno (aav) para uso en terapia de genes de coroideremia.
MX2019008428A (es) Inhibidores de glucosilceramida sintasa.
IN2014CN00688A (es)
EA201391114A1 (ru) Способы использования alk-ингибиторов
MX2014003889A (es) Compuestos antivirales.
EA201171335A1 (ru) Вектор гена
MX2019008122A (es) Derivados de aminas heterociclicas que inhiben la transduccion de se?al mediada por cinasa asociada con el receptor de interleucina-1.
WO2011159684A3 (en) Generation of induced pluripotent stem cells from small volumes of peripheral blood
MX337984B (es) Variantes de alfa amilasa y polinucleotidos que codifican la misma.
MX2013008212A (es) Derivados de 7-azaindol.
EA201370018A1 (ru) Составы рифаксимина и их применение
MX355356B (es) Variantes de alfa-amilasa y polinucleotidos que codifican las mismas.
EP4253534A3 (en) Alpha-amylase variants and polynucleotides encoding same
MX2013004061A (es) Analogos de ciclosporina.
EA201290813A1 (ru) Полиэпитопные конструкции и способы их получения и применения
MX2013004062A (es) Analogos de ciclosporina.
MX351818B (es) Compuestos antivirales.
WO2012154271A3 (en) Method and cells for identifying rig-i pathway regulators
MX2014004735A (es) Adicion de hierro para mejorar cultivo celular.

Legal Events

Date Code Title Description
FG Grant or registration